Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Kineta, Inc. (KANT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/27/2025: KANT (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $0
1 Year Target Price $0
| 0 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -49.16% | Avg. Invested days 17 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/27/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 6.07M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta -3.66 | 52 Weeks Range 0.18 - 1.15 | Updated Date 05/3/2025 |
52 Weeks Range 0.18 - 1.15 | Updated Date 05/3/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.64 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -148.19% | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 5881420 | Price to Sales(TTM) - |
Enterprise Value 5881420 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue 1.29 | Enterprise Value to EBITDA -4.53 | Shares Outstanding 12265500 | Shares Floating 7987147 |
Shares Outstanding 12265500 | Shares Floating 7987147 | ||
Percent Insiders 34.84 | Percent Institutions 5.25 |
Analyst Ratings
Rating - | Target Price - | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Kineta, Inc.
Company Overview
History and Background
Kineta, Inc. is a clinical-stage biotechnology company focused on developing novel immunotherapies to treat cancer. Founded in 2007, the company has transitioned from early-stage research to clinical development of its drug candidates.
Core Business Areas
- Immunotherapies: Focuses on developing novel immunotherapies targeting cancer and other immune-related diseases.
Leadership and Structure
Shawn Iadonato, PhD, is the CEO. The company has a management team with expertise in drug development, clinical trials, and business development.
Top Products and Market Share
Key Offerings
- KVA083: A preclinical anti-CD27 agonist immunotherapy for the treatment of cancer. Competitors include companies developing similar CD27 agonist therapies. Market share data not publicly available as it is in preclinical stages.
- KVA12123: A VISTA-blocking immunotherapy for solid tumors. Competitors include companies developing similar VISTA blocking therapies. Market share data not publicly available as it is in preclinical stages.
Market Dynamics
Industry Overview
The immunotherapy market is rapidly growing, driven by the success of checkpoint inhibitors and other novel approaches to harnessing the immune system to fight cancer.
Positioning
Kineta, Inc. is positioned as an innovator in the immunotherapy space, focusing on novel targets and mechanisms of action.
Total Addressable Market (TAM)
The global immunotherapy market is estimated to be worth billions of dollars. Kineta, Inc. aims to capture a portion of this market through its novel drug candidates.
Upturn SWOT Analysis
Strengths
- Novel immunotherapy targets
- Experienced management team
- Strong intellectual property portfolio
Weaknesses
- Limited financial resources
- Dependence on clinical trial success
- Lack of commercialized products
Opportunities
- Strategic partnerships
- Expansion of pipeline
- Positive clinical trial results
Threats
- Competition from larger pharmaceutical companies
- Clinical trial failures
- Regulatory hurdles
Competitors and Market Share
Key Competitors
- MRK
- BMY
- PFE
- AZN
- GILD
Competitive Landscape
Kineta, Inc. faces competition from established pharmaceutical companies with greater resources and commercialization capabilities. However, its novel targets provide a competitive advantage.
Growth Trajectory and Initiatives
Historical Growth: Kineta, Inc.'s growth is tied to clinical advancements and successful fundraising.
Future Projections: Future growth is projected to be driven by positive clinical trial results and strategic partnerships.
Recent Initiatives: Recent initiatives include advancing its clinical programs and seeking strategic collaborations.
Summary
Kineta, Inc. is a clinical-stage biotechnology company focusing on novel immunotherapies. Its strengths include novel targets and an experienced team, but it faces challenges related to funding and clinical trial success. Positive clinical trial results and strategic partnerships are critical for the company's future growth. The company needs to watch out for larger companies and regulatory hurdles.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings
- Investor presentations
- Industry reports
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Kineta, Inc.
Exchange NASDAQ | Headquaters Mercer Island, WA, United States | ||
IPO Launch date 2016-02-11 | CEO - | ||
Sector Healthcare | Industry Biotechnology | Full time employees 4 | Website https://kinetabio.com |
Full time employees 4 | Website https://kinetabio.com | ||
Kineta, Inc., a clinical-stage biotechnology company, engages in developing immunotherapies that transform patients' lives in the United States. The company's immuno-oncology pipeline includes KVA12123, a VISTA blocking immunotherapy in development as a twice weekly monoclonal antibody (mAb) infusion drug. KVA12123 is being evaluated in a Phase 1/2 clinical trial as a monotherapy and in combination with pembrolizumab in patients with advanced solid tumors, including non-small cell lung, ovarian, renal cell carcinoma, head and neck, renal cell, and colorectal cancers. It also developing anti-CD27 agonist mAb immunotherapy to address the problem of exhausted T cells. It has collaboration and license agreements with MSD International Business GmbH, Genentech, Inc., Merck &Co., Inc., FAIR Therapeutics B.V., and GigaGen, Inc. Kineta, Inc. is headquartered in Mercer Island, Washington.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.